View More View Less
  • 1 Uzsoki Utcai Oktató Kórház, Budapest, Uzsoki u. 29., 1145
  • 2 Uzsoki Utcai Oktató Kórház, Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Absztrakt:

A colorectalis eredetű májáttétek (CRCLM) máig egyetlen kuratív terápiás lehetősége a sebészi reszekció, ma azonban egy komplex ellátás részeként kell tekinteni rá. Nem különíthető el, hogy a májáttétes beteget a sebészek vagy az onkológusok vagy esetleg az invazív radiológusok kezelik. Kizárólag együttes döntések, egymást követő és kiegészítő terápiák segítségével lehet elérni, hogy ezeket a betegeket hosszú távon kezelni lehessen. Az áttétes colorectalis daganatos betegek egy jelentős részére úgy lehet tekinteni, mint akik krónikus betegségben szenvednek. Különösen izgalmas és változó a reszekábilis májáttétek esetén alkalmazható kezelési algoritmusok változatossága. Egyik mindmáig nyitott kérdés a reszekábilis májáttétek előtti kemoterápia hatékonysága és szükségessége. A tanulmány során megkíséreljük összegezni a colorectalis eredetű reszekábilis májáttétek preoperatív onkológiai kezelésének gyakorlatáról szerzett nemzetközi és hazai tapasztalatokat. Orv Hetil. 2018; 159(21): 823–830.

  • 1

    Kanas GP, Taylor A, Promrose JH, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012; 4: 283–301.

  • 2

    Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27: 1386–1422.

  • 3

    Adams RB, Aloia T, Loyer E, et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB 2013; 15: 91–103.

  • 4

    Essadi I, Sbitti Y, Fetohi M, et al. Treatment of liver metastases from colorectal cancer: Medico-surgical strategies. Gastroenterol Res. 2011; 4: 122–124.

  • 5

    Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005; 23: 7125–7134.

  • 6

    Jakab F. Milestones in liver surgery. [Mérföldkövek a máj sebészetében.] Orv Hetil. 2018; 159: 375–383. [Hungarian]

  • 7

    Adam R, de Gramont A, Figueras J, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015; 41: 729–741.

  • 8

    Jones RP, Brudvik KW, Franklin MJ, et al. Precision surgery for colorectal liver metastases: Opportunities and challenges of omics-based decision making. Eur J Surg Oncol. 2017; 43: 875–883.

  • 9

    Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371; 1007–1016.

  • 10

    Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208–1215.

  • 11

    Jones RP, Hamann S, Malik HZ, et al. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer 2014; 50: 1590–1601.

  • 12

    Torzilli G, Adam R, Vigano L, et al. Surgery of colorectal liver metastases: pushing the limits. Liver Cancer 2016; 6: 80–89.

  • 13

    Ayez N, van der Stok EP, de Wilt H, et al. Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. BMC Cancer 2015; 15: 180.

  • 14

    Folprecht G, Gruenberger T, Bechstein W, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010; 11: 38–47.

  • 15

    Choti MA, Thomas M, Wong SL, et al. Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. Ann Surg Oncol. 2016; 23: 375–381.

  • 16

    Krell RW, Reames BN, Hendren S, et al. Surgical referral for colorectal liver metastases: a population-based survey. Ann Surg Oncol. 2015; 22: 2179–2194.

  • 17

    Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon Cancer. Version 2.2017. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx

  • 18

    Yin Z, Liu C, Chen Y, et al. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): Simultaneous or delayed? Hepatology 2013; 57: 2346–2357.

  • 19

    Feng Q, Wei Y, Zhu D, et al. Timing of hepatectomy for resectable synchronous colorectal liver metastases: for whom simultaneous resection is more suitable – a meta-analysis. PloS ONE 2014; 9: e104348.

  • 20

    Slesser AP, Chand M, Goldin R, et al. Outcomes of simultaneous resections for patients with synchronous colorectal liver metastases. Eur J Surg Oncol. 2013; 39: 1384–1393.

  • 21

    Baltatzis M, Chan AK, Jegatheeswaran S, et al. Colorectal cancer with synchronous hepatic metastases: systematic review of reports comparing synchronous surgery with sequential bowel-first or liver-first approaches. Eur J Surg Oncol. 2016; 42: 159–165.

  • 22

    Clinical Practice Guidelines in Oncology (NCCN Guidelines). Rectal Cancer. Version 3.2017. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx

  • 23

    Jones RP, Kokudo N, Folprecht G, et al. Colorectal liver metastases: a critical review of state of the art. Liver Cancer 2016; 6: 66–71.

  • 24

    Jegatheeswaran S, Mason MJ, Hancock HC, et al. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg. 2013; 148: 385–391.

  • 25

    Lam VW, Laurence J, Pang T, et al. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB 2014; 16: 101–108.

  • 26

    Simoneau E, Alanizi R, Alshenaifi J, et al. Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases. J Surg Oncol. 2016; 113: 449–455.

  • 27

    Spelt L, Sparrelid E, Isaksson B, et al. Tumour growth after portal vein embolization with pre-procedural chemotherapy for colorectal liver metastases. HPB 2015; 17: 529–535.

  • 28

    Chun YS, Vauthey JN, Ribero D, et al. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg. 2007; 11: 1498–1504.

  • 29

    Buac S, Schadde E, Schnitzbauer AA, et al. The many faces of ALPPS: surgical indications and techniques among surgeons collaborating in the international registry. HPB 2016; 18: 442–448.

  • 30

    Donati M, Stavrou GA, Oldhafer KJ. Current position of ALPPS in the surgical landscape of CRLM treatment proposals. World J Gastroenterol. 2013; 19: 6548–6554.

  • 31

    Zhu D, Zhong Y, Wei Y, et al. Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. PloS ONE 2014; 9: e86543.

  • 32

    Beppu T, Sakamoto Y, Hayashi H, et al. Perioperative chemotherapy and hepatic resection for resectable colorectal liver metastases. Hepatobiliary Surg Nutr. 2015; 4: 72–75.

  • 33

    Lehmann K, Rickenbacher A, Weber A, et al. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg. 2012; 255: 237–247.

  • 34

    Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007; 94: 274–286.

  • 35

    Zendel A, Lahat E, Dreznik Y, et al. Vanishing liver metastases – a real challenge for liver surgeons. Hepatobiliary Surg Nutr. 2014; 3: 295–302.

  • 36

    Oxenberg J, Papenfuss W, Esemuede I, et al. Multidisciplinary cancer conferences for gastrointestinal malignancies result in measureable treatment changes: a prospective study of 149 consecutive patients. Ann Surg Oncol. 2015; 22: 1533–1539.